Subscribe
istock-839222794-nicoelnino-1
NicoElnino / iStockphoto.com
17 October 2018Americas

Nestlé and Palette in global urological deal

Nestlé Skin Health and Palette Life Sciences have entered into a global licensing agreement intended to improve outcomes for patients with urological and colorectal disorders.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Nestlé health unit sued over injection technology
15 October 2018   Nestlé’s Skin Health unit has been accused of infringing patents and misappropriating trade secrets relating to neurotoxin and derma filler injections.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

More on this story

Americas
Nestlé health unit sued over injection technology
15 October 2018   Nestlé’s Skin Health unit has been accused of infringing patents and misappropriating trade secrets relating to neurotoxin and derma filler injections.

More on this story

Americas
Nestlé health unit sued over injection technology
15 October 2018   Nestlé’s Skin Health unit has been accused of infringing patents and misappropriating trade secrets relating to neurotoxin and derma filler injections.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent